Chemotherapy sensitivity and resistance testing: To be "standard" or to be individualized, that is the question

被引：19

作者：

Kubota T. ^{[1
]}

Weisenthal L. ^{[2
]}

机构：

[1] Center for Advanced and Comprehensive Medicine, Keio University Hospital, Shinjuku-ku, Tokyo 160-8582

[2] Weisenthal Cancer Group, Huntington Beach, CA

来源：

Gastric Cancer | 2006年 / 9卷 / 2期

关键词：

Chemosensitivity testing; Clinical trial; Gastric cancer; Histoculture drug-response assay; MTT assay;

D O I：

10.1007/s10120-006-0366-7

中图分类号：

学科分类号：

摘要：

Radical surgery with extended lymph-node dissection is the treatment of first choice and the only curative treatment for locally advanced gastric cancer. While recent combination chemotherapy with S-1 (a combination of tegafur with two biomodulators, gimeracil and oteracil) has achieved high response rates, controversy still remains regarding the significance of adjuvant cancer chemotherapy after surgery. We have been applying chemosensitivity testing in evaluating the appropriate adjuvant cancer chemotherapy for advanced gastric cancer. Our multiple studies have indicated that this chemosensitivity testing would be useful to improve the results of adjuvant chemotherapy, by increasing survivals in the sensitive group. The chemosensitivity testing is approved as "advanced clinical medicine" by the Japanese Ministry of Health, Welfare, and Labor at 11 institutes at present. While complete lymph-node dissection and chemosensitivity test-guided adjuvant chemotherapy has been reported to result in a survival benefit for patients with advanced gastrointestinal cancer, the clinical utility of the testing should be established by means of prospective, randomized clinical trials. Two pivotal clinical trials have been initiated to clarify the utility of chemosensitivity testing in the selection of the appropriate adjuvant cancer chemotherapy for gastric cancer. © 2006 by International and Japanese Gastric Cancer Associations.

引用

页码：82 / 87

页数：5

共 44 条

[1]

Schipper D.L., Wagener D.J., Chemotherapy of gastric cancer, Anticancer Drugs, 7, pp. 137-149, (1996)

[2]

MacDonald J.S., Gohmann J.J., Chemotherapy of advanced gastric cancer: Present status, future prospects, Semin Oncol, 15, pp. 42-49, (1988)

[3]

Sakata Y., Ohtsu A., Horikoshi N., Sugimachi K., Mitachi Y., Taguchi T., Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1∈M tegafur-0.4∈M gimestat-1∈M otastat potassium) in advanced gastric cancer patients, Eur J Cancer, 34, pp. 1715-1720, (1998)

[4]

Koizumi W., Kurihara M., Nakano S., Hasegawa K., Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. for the S-1 Cooperative Gastric Cancer Study Group, Oncology, 58, pp. 191-197, (2000)

[5]

Koizumi W., Tanabe S., Saigenji K., Ohtsu A., Boku N., Nagashima F., Et al., Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer, Br J Cancer, 89, pp. 2207-2212, (2003)

[6]

Kondo T., Kubota T., Tanimura T., Yamaue H., Akiyama S., Maehara Y., Et al., Cumulative results of chemosensitivity tests for antitumor agents in Japan, Anticancer Res, 20, pp. 2389-2392, (2000)

[7]

Hermans J., Bonenkamp J.J., Boon M.C., Bunt A.M.G., Ohyama S., Sasako M., Et al., Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials, J Clin Oncol, 11, pp. 1441-1447, (1993)

[8]

Pignon J.P., Ducreux M., Rougier P., Meta-analysis of adjuvant chemotherapy in gastric cancer: A critical reappraisal, J Clin Oncol, 12, pp. 877-878, (1994)

[9]

Nakajima T., Ohta K., Ohyama S., Hamajima N., Nakajima T., Yamaguchi T., Meta-analysis of adjuvant chemotherapy trials for gastric cancer at the Cancer Institute Hospital, Multimodality Therapy for Gastric Cancer, pp. 27-31, (1999)

[10]

Earle C.C., Maroun J.A., Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: Revisiting a meta-analysis of randomized trials, Eur J Cancer, 35, pp. 1059-1064, (1999)

← 1 2 3 4 5 →